Long-term relapse prevention

01Role and principlesWho benefits and the main preventive aims.

Relapse prevention is a separate clinical decision after acute symptom control. Review the nature and variable course of bipolar illness, severity and consequences of earlier episodes, residual symptoms, triggers, treatment response, adherence and adverse effects. Ask what recovery means in work, relationships, sleep and independence. Explain both the potential benefit of continued treatment and the risk of recurrence after reduction, while respecting that long-term acceptability determines real-world effectiveness.

NICE offers lithium as first-line long-term pharmacological treatment and describes it as the most effective long-term medicine for bipolar disorder. It requires reliable blood monitoring, stable fluid and salt intake, interaction awareness and renal, thyroid and calcium surveillance. If lithium is ineffective, poorly tolerated or unsuitable, an antipsychotic such as asenapine, aripiprazole, olanzapine, quetiapine or risperidone can be considered according to episode polarity, prior response and harms.

Pharmacological escalation remains ordered. If the first maintenance antipsychotic is poorly tolerated at any dose, including rapid weight gain, or ineffective at its licensed maximum, consider an alternative from the recommended group. If the alternative is ineffective, specialist consideration may turn to valproate combined with an antipsychotic or lithium. Apply current MHRA safeguards, formulation-specific licensing and reproductive counselling before any valproate decision; a previous prescription never removes current duties.

Psychological prevention is active treatment, not generic support. Offer a manualised intervention designed for bipolar disorder, delivered individually, in a group or with family. It should provide information, relate thoughts and behaviour to mood, develop self-monitoring, address distress and functioning, create relapse plans and use problem solving for communication and practical difficulties. Family intervention can clarify supportive roles without transferring clinical responsibility to relatives.

A written relapse plan turns monitoring into action. Specify personal early signs of mania and depression, usual sequence, triggers, protective routines, coping steps, medication arrangements and who to contact. Record what may be shared and revisit consent when well. If medication is stopped, taper gradually using the medicine-specific instructions, monitor closely during reduction and continue symptoms, mood and mental-state monitoring for two years after complete cessation.

Key points

After every manic or bipolar depressive episode, review long-term prevention, previous consequences, residual symptoms, effective treatments, patient priorities and reproductive plans.
Offer a structured individual, group or family psychological intervention designed for bipolar disorder to prevent relapse or address persisting inter-episode symptoms.
First-line long-term pharmacological treatment is lithium; NICE explains that it is the most effective maintenance medicine for bipolar disorder.
If lithium is ineffective, poorly tolerated or unsuitable, consider one appropriate antipsychotic; if that trial fails or causes rapid weight gain, consider another recommended antipsychotic.
Only after the alternative antipsychotic is ineffective should valproate combination with an antipsychotic or lithium be considered, subject to all current MHRA restrictions.
Use the person's episode history to identify a relapse signature: earliest sleep, energy, thought, activity, spending, social and depressive changes, not generic warning lists.
Agree coping actions, who may receive information, named primary and secondary care contacts and circumstances for urgent review or a pre-agreed medication response.
If long-term medication stops, taper according to the medicine-specific schedule, teach early signs and continue mood and mental-state monitoring for two years after it ends completely.
Provide at least annual comprehensive physical-health review, with additional drug-specific lithium, antipsychotic or valproate monitoring at the required frequency.

02Assessment and patient selectionRisk features, eligibility and important cautions.

High recurrence burden

Frequent, severe or dangerous previous episodes and incomplete inter-episode recovery increase the potential value of sustained prevention.

Residual symptom signal

Subthreshold depression, irritability, sleep change or cognitive and functional difficulty may precede relapse and also require rehabilitation.

Personal relapse signature

A reproducible sequence of sleep, energy, thought, social or behavioural change provides a more usable warning system than generic symptoms.

Treatment adherence barrier

Adverse effects, stigma, complexity, poor insight, cost, monitoring access or previous coercion may undermine a theoretically effective maintenance plan.

Physical-health vulnerability

Cardiometabolic disease, renal or thyroid change, pregnancy and medicine interactions alter the benefit-harm balance and monitoring intensity.

Red flags requiring action

A rapid fall in sleep need with increasing energy, speech or spending can precede mania and requires prompt use of the agreed escalation plan.
Hopelessness, withdrawal, stockpiling medication, farewell behaviour or renewed self-harm overrides the timetable for ordinary relapse-prevention review.
Pregnancy, planning pregnancy or a partner-conception plan can materially alter lithium or valproate decisions and requires timely specialist review without abrupt self-discontinuation.
Vomiting, diarrhoea, dehydration, new interacting medicines, ataxia, coarse tremor or confusion during lithium treatment suggests toxicity risk and needs urgent action.
Rapid weight gain, new hyperglycaemic symptoms, syncope, severe movement disorder or other medically important antipsychotic effects require earlier physical and prescription review.

03Baseline assessmentMeasurements that guide the plan and track progress.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Episode and consequence reviewFirst step
Why
Map polarity, frequency, severity, triggers, harms, recovery and previous treatment response across the illness.
Interpretation and limitations
The pattern guides prevention intensity and agent choice; past response is informative but does not guarantee future benefit or tolerability.
02
Shared adherence assessment
Why
Identify missed doses, beliefs, adverse effects, formulation issues, monitoring access and practical barriers.
Interpretation and limitations
Correct remediable obstacles before declaring treatment failure; non-adherence is information for formulation, not a moral diagnosis.
03
Annual comprehensive health check
Why
Assess weight, diet, activity, pulse, blood pressure, glucose or HbA1c, lipids, liver and indicated renal, thyroid and calcium measures.
Interpretation and limitations
Treat abnormalities rather than merely recording them, and communicate results between primary care, care coordinator and psychiatrist.
04
Drug-specific monitoring review
Why
Confirm lithium levels and organ tests, antipsychotic metabolic checks or valproate blood, liver and reproductive safeguards.
Interpretation and limitations
Maintenance prescriptions remain conditional on current monitoring and circumstances; a normal historical result does not fulfil a due check.
05
Relapse-plan usability test
Why
Check whether warning signs, actions, contacts, consent choices and access routes work in the person's actual setting.
Interpretation and limitations
A plan is effective only if the patient and supporters can recognise the trigger and complete the next step at the time required.

04InterventionsLifestyle, treatment and escalation options.

01First-line pharmacological preventionOffer monitored lithium treatmentFirst stepFirst lineLong-term medication is being planned after a bipolar episode and lithium is acceptable and clinically suitable.

1Discuss episode history, lithium's relative long-term effectiveness, monitoring burden, toxicity, interactions, pregnancy implications and the person's priorities.
2Complete baseline tests, establish specialist initiation and shared-care responsibilities and titrate to a guideline target using correctly timed plasma levels.
3Combine medicine with structured psychological prevention, physical-health care and a written relapse and sick-day action plan.

02Lithium is unsuitableUse ordered antipsychotic alternativesLithium is ineffective, poorly tolerated or unsuitable after a shared and clinically informed assessment.

1Select one maintenance antipsychotic from prior episode response, polarity, metabolic, movement, cardiac, prolactin and reproductive considerations.
2Monitor an explicit therapeutic trial and switch to another recommended antipsychotic if poorly tolerated or ineffective at the licensed maximum.
3Seek specialist review before later valproate combination and document why restrictions, licence, interactions and monitoring permit the chosen regimen.

03Planned discontinuationTaper and monitor beyond the last doseA stable patient makes an informed decision to stop long-term pharmacological treatment.

1Review relapse history, current stress, pregnancy plans, alternatives and the medicine-specific withdrawal schedule and agree early-warning actions.
2Reduce gradually at the required medicine-specific pace with closer symptom and safety review during and after the taper.
3Continue monitoring mood, symptoms and mental state for two years after treatment stops completely and preserve rapid re-entry to specialist care.

05Medicines and treatment safetyRegimens, contraindications and review points.

NICE first-line and most effective long-term pharmacological treatment for bipolar relapse prevention when monitoring is acceptable and safe.

Lithium carbonate prolonged-release

Initiate only with specialist and shared-care monitoring; individualise the oral dose to a correctly timed plasma concentration, usually aiming for 0.6 to 0.8 mmol/L when lithium is prescribed for the first time.

A narrow therapeutic index requires renal, thyroid, calcium and level monitoring, consistent hydration and salt intake, pregnancy discussion and avoidance or close management of NSAIDs, ACE inhibitors, ARBs and diuretics.

A possible antipsychotic alternative when lithium is ineffective, poorly tolerated or unsuitable, particularly following an aripiprazole-responsive manic episode.

Aripiprazole oral

For recurrence prevention after a manic episode that responded to aripiprazole, continue the same once-daily dose; adult manic treatment commonly starts at 15 mg daily and must not exceed 30 mg daily.

Monitor akathisia, activation, impulse-control problems, movement effects, orthostasis and metabolic parameters; review interactions, pregnancy and whether the agent adequately covers the person's depressive relapse pattern.

06Targets, monitoring and follow-upResponse, safety and longer-term review.

Review mood, sleep, energy, thought pace, psychosis, depressive withdrawal, suicide risk and individual relapse signs at intervals matched to episode history and treatment change.
Perform the comprehensive physical-health check at least annually and complete more frequent lithium, antipsychotic or valproate monitoring when the regimen requires it.
At every long-term review ask about adverse effects, adherence, interacting medicines, substances, contraception, pregnancy intentions and the feasibility of the monitoring plan.
Test the crisis plan after moves, relationship change, new clinicians or altered prescriptions so contact details, consent choices and available means remain current.
During discontinuation increase review frequency and continue monitoring symptoms, mood and mental state for two years after the final dose.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Prevention follows polarity

Past manic and depressive burden, not merely the most recent episode, should influence whether a maintenance option covers the person's main risks.

Adherence is an outcome

A slightly less preferred medicine that the person can tolerate, monitor and take may prevent more relapse than an unacceptable theoretical optimum.

Family roles need boundaries

Supporters can notice sleep or spending changes, but the plan should not make them sole risk managers or breach agreed confidentiality.

Stopping is an intervention

A taper needs timing, monitoring and rapid-access arrangements; simply allowing prescriptions to lapse is not a safe discontinuation strategy.

Recovery extends beyond symptoms

Employment, cognition, relationships, physical health and confidence may require active rehabilitation even when episode criteria have resolved.

08Common pitfallsFrequent interpretation and management errors.

01
Renewing the acute treatment indefinitely without a separate long-term benefit and harm discussion.
02
Presenting lithium as optional only after antipsychotics instead of the NICE first-line maintenance medicine.
03
Labelling a drug ineffective before addressing adherence, dose, monitoring access and residual substance or sleep disruption.
04
Using valproate combination without current MHRA reproductive safeguards and exact product licensing review.
05
Offering generic supportive counselling in place of a structured bipolar-specific relapse-prevention intervention.
06
Writing a crisis plan with vague advice such as seek help but no personal trigger, named contact or response time.
07
Ending follow-up when the last maintenance dose is taken rather than monitoring for the recommended two years.